,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2013-04-10 03:10:00,"Roche ( RHHBY ) recently announced an alliance with Isis Pharmaceuticals, Inc ( ISIS ) to develop therapies for Huntington's disease (HD).",0.8817700147628784,0.012669249437749386,0.10556074976921082,positive,0.8691007494926453
1,2013-04-10 03:10:00,This alliance will combine Isis' antisense oligonucleotide (ASO) technology with Roche's scientific expertise to develop neurodegenerative therapeutics for treating HD.,0.8261783123016357,0.011564766988158226,0.16225694119930267,positive,0.8146135210990906
2,2013-04-10 03:10:00,"Isis develops antisense drug discovery programs targeting cardiovascular, severe and rare neurologic and metabolic diseases and cancer.",0.12255510687828064,0.0051231286488473415,0.8723217248916626,neutral,0.11743197590112686
3,2013-04-10 03:10:00,"In addition, Roche will combine its proprietary brain shuttle technology with Isis ASO technology to enable systemic administration of antisense drugs for treating asymptomatic patients.",0.7850000858306885,0.010908015072345734,0.20409201085567474,positive,0.7740920782089233
4,2013-04-10 03:10:00,"As per the agreement, Roche will make an upfront payment of $30 million to Isis.",0.2294939160346985,0.007899518124759197,0.7626065611839294,neutral,0.22159439325332642
5,2013-04-10 03:10:00,The total payment comprising license fee and pre- and post-licensing milestone payments is expected to touch $362 million including potential commercial milestone payments up to $80 million.,0.05217492952942848,0.005232101771980524,0.942592978477478,neutral,0.046942826360464096
6,2013-04-10 03:10:00,"Additionally, Isis is eligible to receive royalties on sales of the drugs whereas Roche has the option to license the drugs from Isis through the completion of the first phase I trial.",0.10366926342248917,0.0058837104588747025,0.8904470801353455,neutral,0.09778555482625961
7,2013-04-10 03:10:00,"Before Roche exercises this option, Isis will be responsible for discovering and developing of an antisense drug targeting huntingtin (HTT) protein in collaboration with Roche.",0.25318753719329834,0.009501856751739979,0.7373105883598328,neutral,0.24368567764759064
8,2013-04-10 03:10:00,"Once Roche exercises its option, it will be responsible for the global development, regulatory and commercialization activities for all drugs resulting from the alliance.",0.10406959801912308,0.004767011385411024,0.8911633491516113,neutral,0.09930258989334106
9,2013-04-10 03:10:00,"As per Roche, currently there is no effective cure for HD.",0.03197341784834862,0.34688135981559753,0.6211452484130859,neutral,-0.3149079382419586
10,2013-04-10 03:10:00,We are positive on the deal with Isis as the market for HD represents a huge unmet medical need.,0.8503682613372803,0.013576635159552097,0.1360551118850708,positive,0.8367916345596313
11,2013-04-10 03:10:00,The deal comes close on the heels of the Japanese approval of the subcutaneous injectable version of Roche's rheumatoid arthritis (RA) drug Actemra (tocilizumab).,0.9127230048179626,0.01622200757265091,0.07105501741170883,positive,0.8965010046958923
12,2013-04-10 03:10:00,The subcutaneous version of the drug has been approved for treating RA patients who have not responded adequately to one or more existing medications for the disease.,0.6097174286842346,0.027255238965153694,0.36302727460861206,positive,0.5824621915817261
13,2013-04-10 03:10:00,Actemra primarily faces competition from AbbVie Inc.'s ( ABBV ) Humira in the RA space.,0.08501745015382767,0.02270924672484398,0.8922732472419739,neutral,0.06230820342898369
14,2013-04-10 03:10:00,To read this article on Zacks.com click here.,0.017961200326681137,0.01924508437514305,0.9627937078475952,neutral,-0.001283884048461914
15,2013-04-10 03:10:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204566642642021,0.015637893229722977,0.9741575717926025,neutral,-0.0054333265870809555
